Results 101 to 110 of about 31,861 (267)

Subcutaneous anakinra in the management of refractory MIS-C in France

open access: yesFrontiers in Pediatrics
IntroductionMultisystemic inflammatory syndrome in children (MIS-C) is a therapeutic emergency and can lead to myocardial dysfunction (17%–75%) and heart failure (52%–53%).
Perrine Dusser   +8 more
doaj   +1 more source

Impact of an Interleukin-1 Receptor Antagonist and Erythropoietin on Experimental Myocardial Ischemia/Reperfusion Injury

open access: yesThe Scientific World Journal, 2012
Background. Revascularization of infarcted myocardium results in release of inflammatory cytokines mediating myocardial reperfusion injury and heart failure. Blockage of inflammatory pathways dampens myocardial injury and reduces infarct size.
Christina Grothusen   +6 more
doaj   +1 more source

The Use of IL-1 Receptor Antagonist (Anakinra) in Idiopathic Recurrent Pericarditis: A Narrative Review

open access: yesCardiology Research and Practice, 2016
Recurrent pericarditis is a complication of acute pericarditis in 20–30% of the patients and is usually idiopathic in nature. The underlying pathogenesis of this condition remains unclear, although immune-mediated mechanisms seem likely.
Shankar Baskar   +2 more
doaj   +1 more source

IL-1β inhibition in cardiovascular complications associated to diabetes mellitus [PDF]

open access: yes, 2017
Diabetes mellitus (DM) is a chronic disease that affects nowadays millions of people worldwide. In adults, type 2 diabetes mellitus (T2DM) accounts for the majority of all diagnosed cases of diabetes.
Carraro, Raffaele   +3 more
core   +2 more sources

Long‐term echocardiographic findings in patients with idiopathic recurrent pericarditis treated with anakinra

open access: yesInternal Medicine Journal, EarlyView.
Abstract Aim Idiopathic recurrent pericarditis (IRP) is considered an autoinflammatory disease, and interleukin 1 inhibitors, such as anakinra, are used to treat resistant cases. Constrictive pericarditis, a feared complication, continues to be a critical concern. In the biologic era, evidence on long‐term transthoracic echocardiographic (TTE) findings
Zeynep Toker Dincer   +5 more
wiley   +1 more source

New treatment strategies for growth failure caused by chronic inflammation in children [PDF]

open access: yes, 2013
Chronic inflammation during childhood often leads to impaired bone growth and reduced height in adulthood. Interleukin-1β (IL-1β), interleukin-6 (IL-6) and the tumour necrosis factor-α (TNF-α) are pro-inflammatory cytokines up-regulated during chronic ...
Fernández Vojvodich, Paola
core   +1 more source

Dermatologic Findings of RELA‐Associated Autoinflammatory Disease

open access: yesPediatric Dermatology, EarlyView.
ABSTRACT Variants in the gene RELA have been implicated in a monogenic, hereditary form of Behcet's‐like syndrome. This case series describes the dermatologic manifestations of three patients with identified RELA‐associated autoinflammatory disease.
Elizabeth Nourse   +4 more
wiley   +1 more source

IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone? [PDF]

open access: yes, 2016
Although in the past the prevention of joint destruction in rheumatoid arthritis (RA) was strongly emphasized, now a great interest is focused on associated comorbidities in these patients. Multiple data suggest that a large percentage of RA patients are
Alvaro, S.   +10 more
core   +1 more source

NEMO‐NDAS: Case Report and Review of the Literature

open access: yesPediatric Dermatology, EarlyView.
ABSTRACT NEMO‐deleted exon 5 autoinflammatory syndrome (NEMO‐NDAS) is the result of a gain‐of‐function IKBKG pathogenic variant leading to dysregulated NF‐κB signaling and systemic inflammation. We present a case of NEMO‐NDAS in a 2‐year‐old female presenting with recurrent fevers, subcutaneous nodules, lymphadenopathy, and splenomegaly.
Angela Yang   +5 more
wiley   +1 more source

New drugs: Anakinra [PDF]

open access: diamond, 2004
Janette Donovan   +79 more
openalex   +1 more source

Home - About - Disclaimer - Privacy